A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis

Summary

This study is designed to evaluate safety and assess initial efficacy of VX-509, a JAK3 inhibitor, for treatment of subjects with active RA. This study will assess the clinical response of 4 doses of VX-509 compared to placebo when administered for 12 weeks to patients with active RA. The study will also evaluate the safety and tolerability of VX-509 compared to placebo when administered for 12 weeks to subjects with active RA.

Timeline

Start

2010-02

Primary completion

2011-07

Completion

2011-07

Drugs

Indications